Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
Healthcare
$84.83 -1.25%
-$1.03 today
- Market cap
- $4.78B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
52W Low $16.64High $96.50
Volume 0.89M
Average 0.82M
Income Statement
Follow revenue through to earnings.
Revenue
$2.04M
FY 2025 · Annual
-67.3% YoYOperating Income
-$177.93M
FY 2025 · Annual
Net Income
-$162.34M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 12.61M | 29.38M | 32.84M | 83.11M | 145.64M |
| Selling, General & Admin | 1.96M | 6.74M | 18.16M | 24.99M | 34.33M |
| Operating Expenses | 14.56M | 36.12M | 51M | 108.1M | 179.97M |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| EBITDA | (11.09M) | (28.33M) | (43.2M) | (84.56M) | (161.91M) |
| EBITDA Margin | -751.3% | -441.5% | -1528.7% | -1356.2% | -7952.3% |
| Operating Income | (13.09M) | (29.71M) | (48.17M) | (101.86M) | (177.93M) |
| Operating Margin | -886.6% | -462.9% | -1704.7% | -1633.7% | -8739.3% |
| Interest Income | 100K | 1.15M | 4.76M | 17.37M | 16.12M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (23K) | 1.23M | 4.62M | 16.9M | 15.6M |
| Income Before Tax | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Pre-Tax Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.11M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Net Margin | -888.1% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
| EPS (Basic) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| EPS (Diluted) | (3.82) | (7.60) | (8.45) | (2.55) | (4.20) |
| 3.43M | 3.75M | 5.15M | 33.31M | 37.79M | |
| 3.43M | 3.75M | 5.15M | 33.31M | 37.79M |
DNTH Earnings Waterfall · TTM
NASDAQ:DNTH · Revenue to Net Income
Key Ratios
EPS$-0.13
Gross Margin95.9%
Net Margin2442.9%
P/E Ratio-14.5
P/S Ratio6280.7
Analysis
$1.9M of revenue converted into -$29.9M of net income for the selected period. Gross margin is 95.9% and net margin is 2442.9%, showing how much revenue survives after costs and taxes. EPS is $-0.13, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| SC 13G | SC 13G filing | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 18, 2026 |
How much revenue does DNTH generate?
Dianthus Therapeutics, Inc. (DNTH) reported $2.04M of revenue in fiscal 2025.
Is DNTH profitable?
Dianthus Therapeutics, Inc. (DNTH) reported -$162.34M of net income, with a net margin of -7973.3%.
Continue the stock analysis
Jump to another research area for this company.